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Abstract 
Chromatin remodeler proteins exert an important function in promoting dynamic 
modifications in the chromatin architecture, performing a central role in 
regulating gene transcription. Deregulation of these molecular machines may 
lead to striking perturbations in normal cell function. The CHD7 gene is a 
member of the chromodomain helicase DNA-binding family and, when mutated, 
has been shown to be the cause of the CHARGE syndrome, a severe 
developmental human disorder. Moreover, CHD7 has been described to be 
essential for neural stem cells and it is also highly expressed or mutated in a 
number of human cancers. However, its potential role in glioblastoma has not 
yet been tested. Here we show that CHD7 is up-regulated in human glioma 
tissues and we demonstrate that CHD7 knockout (KO) in LN-229 glioblastoma 
cells suppresses anchorage-independent growth and spheroid invasion in vitro. 
Additionally, CHD7 KO impairs tumor growth and increases overall survival in 
an orthotopic mouse xenograft model. Conversely, ectopic overexpression of 
CHD7 in LN-428 and A172 glioblastoma cell lines increases cell motility and 
invasiveness in vitro and promotes LN-428 tumor growth in vivo. Finally, RNA-
seq analysis revealed that CHD7 modulates a specific transcriptional signature 
of invasion-related target genes. Further studies should explore clinical-
translational implications for glioblastoma treatment. 
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Introduction 
Chromatin remodeler proteins comprise a special class of enzymes which 
modify chromatin structure, thereby playing an essential role in modulating gene 
expression patterns 1. The CHD proteins are ATP-dependent chromatin 
remodelers which utilize the energy from ATP hydrolysis to slide nucleosomes, 
dissociate core histones, or relocate entire histone octamers 2. Abnormal 
activity of these molecular machines may result in a multitude of deregulated 
cellular programs, affecting cell survival, cell death, or malignant transformation 
in a cell type-specific fashion 3. 
Over 90% of the patients displaying clinically typical CHARGE syndrome carry 
mutations in CHD7 4, highlighting the role of this protein in regulating gene 
expression during tissue development and maintenance. Chd7-null mouse 
embryos lose viability by E11 5, whereas heterozygozity in mouse, Xenopus and 
zebrafish models recapitulate many of the malformations present in CHARGE 
patients 6–9. 
Functional studies showed that CHD7 binding sites display features of enhancer 
elements, predominantly decorated with high levels of mono-methylated histone 
H3K4 in a cell type- and stage-specific manner 10–12. In addition, CHD7 
cooperates with PBAF (Polybromo-associated BAF) complexes in Xenopus 
neural crest cells to regulate crucial transcription factors, allowing for the 
acquisition of multipotency and migratory potential 7. Using both proteomic and 
genomic approaches, CHD7 was also found to be a transcriptional cofactor of 
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the essential neural stem cell (NSC) regulator, Sox2, suggesting a role for 
CHD7 in neurogenesis13. In this context, CHD7 was shown to be critical for 
activation of the neural differentiation program of NSC and progenitors in the 
adult mouse brain 14 and its inactivation resulted in loss of stem cell quiescence, 
leading to significant decline in the number of newborn neurons 15. 
Frequent mutations of CHD7 and/or altered gene expression have been 
reported in different human cancers 16–19. CHD7 (formerly known as KIAA1416) 
has been reported to be up-regulated in colon cancers 20 and CHD7 gene 
rearrangement was suggested to be a driver mutation in small-cell lung cancer 
21. Additionally, low CHD7 expression was associated with improved outcome in 
patients with pancreatic ductal adenocarcinoma treated with gemcitabine 22. 
However, the potential contribution of CHD7 to glioblastoma tumor biology had 
not yet been tested. Using a candidate gene approach, we set out to investigate 
a possible role for CHD7 in glioblastoma, given its pivotal role for NSC function 
and the evidence for CHD7 alterations in other tumor types. 
Results 
CHD7 expression is up-regulated in gliomas 
To investigate a potential role for CHD7 in human glioblastoma, we first 
examined CHD7 mRNA levels across all glioma grades 23 using the Cancer 
Genome Atlas Project (TCGA) database. Public microarray database analyses 
revealed that CHD7 is up-regulated in tumor samples, when compared to 
normal brain tissue (NBT) (Fig. 1A), even though no significant alteration in 
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genetic copy number was detected (see supplementary Fig. S1 online). 
Moreover, we found that CHD7 exhibited different expression patterns when 
comparing the four transcriptionally defined glioblastoma subtypes 24 with higher 
levels in the proneural tumor samples (Fig. 1B). 
Consistent with the TCGA interrogation, we confirmed increased CHD7 mRNA 
levels in glioma tissues by qRT-PCR (Fig. 1C). Next, we examined the 
presence of CHD7 expressing cells by immunohistochemistry in glioblastoma 
patient samples. We show that cells displaying high level of CHD7 protein are 
found within the tumor mass in the three different samples analyzed (Fig.1D 
and supplementary Fig. S1 online). Altogether, these results show that CHD7 is 
up-regulated in at least a subset of gliomas irrespective of the grade. 
CHD7 expression is highly heterogeneous in human glioblastoma-derived 
cell lines in vitro 
To further characterize CHD7 expression in glioblastoma, we used the CD133 
cell surface marker to enrich for the glioblastoma-initiating cell (GIC) population 
25 from freshly dissected tumors. As measured by qRT-PCR, CHD7 mRNA 
levels were higher in CD133neg sub-populations (Fig. 2A). 
We next analyzed CHD7 mRNA and protein levels in a panel of eight human 
long-term glioblastoma cell lines (LTCs) and five GIC lines. We found that 
CHD7 is expressed in the vast majority of human glioblastoma-derived cell lines 
in vitro (Fig. 2B). In order to assess the CHD7 protein subcellular localization, 
we optimized immunoblotting with fractionated cytoplasmic and nuclear cell 
  
6 
 
extracts, confirming CHD7 protein localization in the nucleus (Fig. 2C). Since 
CHD7 is mainly concentrated in the nucleus, we heretofore adopted blotting 
nuclear cell extracts instead of whole cell lysates in order to enhance CHD7 
protein detection. Among the LTCs, the highest CHD7 protein levels were found 
in LN-229 cells, whereas T-269 cells displayed higher CHD7 protein levels 
among the GICs (Fig. 2D). Taken together, these results suggest that CHD7 is 
up-regulated in gliomas and its expression is highly heterogeneous in cultured 
glioblastoma cell lines. 
CHD7 deletion attenuates anchorage-independent growth and spheroid 
invasion in LN-229 glioblastoma cell clones in vitro 
Although CHD7 expression was not significantly correlated to patient prognosis 
(see supplementary Fig. S2 online), the great heterogeneity within glioblastoma 
tumors prompted us to further examine the functional impact of CHD7 in 
glioblastoma cells endogenously expressing contrasting levels of this protein. 
Initially, we set out to investigate the effect of CHD7 loss-of-function in 
glioblastoma lines naturally expressing high levels of CHD7. For that purpose, 
we used the CRISPR/Cas9 genome editing technique to abrogate its 
expression in LN-229 cells. 
Cells were transiently transfected with a combination of two different 
sgRNA/Cas9 constructs, targeting the initial and final region of the CHD7 gene, 
aiming to delete most coding exons of CHD7 gene or generate frame shift 
mutations. After confirming, by PCR, the deletion of genomic DNA in the cell 
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population, we undertook single cell sorting in order to isolate cell clones (Fig. 
3A, B). A total of 50 clones were expanded and PCR genotyped, showing that 
only a few clones presented the fragment deletion, while the amplification 
targeting the exon 3 sequence was also detected (Supplementary Fig. S3 
online). Even though CHD7 deletion did not seem to occur in both alleles, 
CHD7 immunoblotting showed that several samples did not express the CHD7 
protein corresponding to the canonical transcript. Two independent cell clones, 
in which CHD7 protein was rendered undetectable (KO), along with two control 
clones, in which CHD7 expression was not altered (WT), were isolated for 
further analyses (Fig. 3C).”  All of these cell clones were successfully expanded 
in culture without any obvious loss in viability, although clone KO-1 displayed a 
slightly decreased, albeit significant, difference in growth rate (Fig. 3D). 
Next, we analyzed anchorage-independent growth in a soft-agar colony 
formation assay. The total number of colonies greater than 50 µm diameter, 
was consistently decreased in the KO cell clones, when compared to the WT 
clones (Fig. 3E). Since anchorage-independent cell growth is associated with 
neoplastic transformation and metastatic potential, we asked whether the 
invasion capacity would be affected in the LN-229 KO clones. To that end, we 
used a 3D-collagen invasion assay to assess invasion in the LN-229 
multicellular spheroids, at 24, 48 and 72 h culturing in a serum-containing 
collagen matrix (Fig. 3F). The area covered by the invading cells was reduced 
by about two-fold in the KO clones after 24 h, when compared to the CHD7 
expressing clones. The invaded area remained significantly reduced over time, 
indicating that the invasive potential of the cells was impaired upon CHD7 
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deletion. Therefore, we demonstrated that CHD7 is not essential for LN-229 cell 
survival in vitro, however, its deletion affects their anchorage-independent 
growth and invasiveness. 
Ectopic CHD7 overexpression elicits LN-428 cell migration and invasion in 
vitro 
To determine whether the reduced cell invasion capacity observed in LN-229 
KO cell clones might originate from a direct effect of CHD7 deletion, we 
selected the LN-428 cell line, which expresses low level of endogenous CHD7 
protein, to generate a cell population that constitutively overexpresses CHD7 
(OE). To this end, the full-length CHD7 cDNA was cloned into the mammalian 
pCXN2-DEST expression vector harboring a very strong promoter for 
mammalian cells (see supplementary Fig. S4 online). LN-428 cells were 
transfected with the empty vector (EV) or the CHD7-expressing construct and 
the G418-resistant polyclonal cell populations were selected and expanded for 
further analysis. Quantification by qRT-PCR and immunoblotting confirmed 
CHD7 overexpression in the LN-428 cell line (Fig. 4A). 
We first performed a scratch wound healing assay and we observed that OE 
cells possessed approximately 30% increased migration potential compared to 
EV (Fig. 4B). We also found that CHD7 ectopic expression increased, by almost 
two-fold, the transwell migration capacity of LN-428 cells (Fig. 4C). We further 
investigated the role of CHD7 in modulating tumor cell invasion using the 
Matrigel invasion assay. CHD7 significantly enhanced, by about six-fold, the 
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invasion capacity of LN-428 cells across the transwell chamber, when 
compared to cells transfected with the EV (Fig. 4D).  
Immunofluorescence staining of actin filaments was carried out to evaluate 
whether cytoskeletal alterations could be associated with altered cell motility 
capacity. We observed over 40% increase in the number of cells displaying 
stress fibers in OE cells when compared to cells which do not express high 
levels of the protein (Fig. 4E, F and supplementary Fig. S5). 
Similarly, A172 OE cells display significant changes in cell motility and 
invasiveness, although in a lesser extend (see supplementary Fig. S6 online). 
Together, these data strongly indicate that CHD7 plays an important role in 
glioblastoma cell migration and invasion. 
CHD7 modulates tumor growth in orthotopic xenograft mouse glioma 
models 
To investigate whether CHD7 is relevant for tumor development and 
progression, we analyzed whether perturbation of CHD7 protein levels affects 
the tumorigenic potential of glioblastoma cells in an orthotopic xenograft murine 
glioma model. Athymic nude mice were used for stereotactical implantation of 
cells derived from one LN-229 WT clone and two KO clones (n=8). To measure 
tumor volume, three pre-randomized mice of each group were sacrificed on the 
day when the first animal developed neurological symptoms. Analysis of brain 
sections showed that none of the animals injected with KO cell clones 
developed big tumors at the time point analyzed, suggesting a delay in tumor 
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growth progression (Fig. 5A, B). Likewise, mice inoculated with the KO-1 clone 
experienced prolonged survival rate compared to the WT clone, whereas 
animals injected with clone KO-2 cells showed a similar effect, although the 
differences were not statistically significant when compared to the WT clone 
(Fig. 5C). 
In a similar setting, animals were inoculated with LN-428 OE and EV and the 
tumor volume was measured (n=3). The tumor size was significantly increased 
in OE group, when compared to EV (Fig. 5D). Immunohistochemistry of brain 
sections showed that cells displaying high protein levels are located at the 
border of the tumor (Fig. 5E) suggesting a correlation between the levels of 
ectopic CHD7 overexpression and the migration and invasion phenotypes of 
LN-428 cells in vivo. 
Altogether, our results demonstrate that functional deletion of CHD7 in human 
glioblastoma cells that express high levels of CHD7, may lead to decreased 
tumor progression, whereas ectopic overexpression of this protein in human 
glioblastoma cells which express low levels of CHD7, enhances tumor growth 
and increases cell invasiveness in vivo. 
Modulation in CHD7 levels altered the expression of adhesion molecules 
Due to the apparent association of CHD7 with glioblastoma pathogenesis, as 
well as the previously described function of CHD7 in gene transcription 10,11,13, 
we set out to perform gene expression profiling aimed at gathering molecular 
insights of the role of CHD7 in human glioblastoma.  For that purpose, we 
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carried out whole transcriptome/RNA-seq analysis of those same engineered 
cell lines in which CHD7 expression has been perturbed. 
The comparison between three distinct WT and three isolated CHD7 KO LN-
229 cell clones, reveled 307 differentially expressed genes (DEGs) whose 
expression was significantly altered (FDR < 0.05; abs(LFC) > 1, case over 
control; see supplementary Fig. S7 and supplementary Table S4 online). In LN-
428 cells, we identified 869 DEGs in OE when compared to EV transfected cells 
(see supplementary Fig. S7 and supplementary Table S5 online). 
Notably, 58 transcripts were commonly regulated in both cell lines, whereas 18 
presented alterations in opposite directions in the expression levels between 
these two groups (Table 1). 
Table 1: Commonly regulated DEGs between LN-229 KOxWT and LN-428 
OExEV. The list presents the DEGs which showed expression level changes in 
opposite directions, with fold change (FC) values expressed as log2 scale over 
control. Negative and positive values indicate down-regulation and up-
regulation of gene expression, respectively. Genes are listed in descending 
order of FC values in OE. Bold DEGs indicate genes with decreased expression 
in KO and increased expression in OE, followed by the other genes which 
showed increase expression in KO and decreased expression in OE. Significant 
changes were considered for FDR < 0.05; abs (LFC) > 1, case over control. 
 
Symbol Name LN-229 
KO 
LN-428 
OE 
CHD7 Chromodomain Helicase DNA Binding 
Protein 7 
-1.8 2.8 
AIF1L Allograft Inflammatory Factor 1 Like -1.8 1.5 
ZNF502 Zinc Finger Protein 502 -5.0 1.0 
C4orf26 Odontogenesis Associated 
Phosphoprotein 
4.8 -1.2 
FRMPD4 FERM And PDZ Domain Containing 4 1.2 -1.2 
MSC-AS1 MSC Antisense RNA 1 2.4 -1.2 
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ABCA1 ATP Binding Cassette Subfamily A 
Member 1 
1.0 -1.3 
CCL5 C-C Motif Chemokine Ligand 5 3.3 -1.3 
KIF26B Kinesin Family Member 26B 1.5 -1.4 
PXYLP1 2-Phosphoxylose Phosphatase 1 1.0 -1.6 
SLCO1A2 Solute Carrier Organic Anion Transporter 
Family Member 1A2 
1.2 -1.6 
CHMP1B2
P 
Charged Multivesicular Body Protein 
1B2, Pseudogene 
2.0 -1.7 
MYH16 Myosin Heavy Chain 16 Pseudogene 1.9 -2.1 
RN7SL2 RNA, 7SL, Cytoplasmic 2 1.4 -2.1 
RN7SL3 RNA, 7SL, Cytoplasmic 3 1.2 -2.2 
HAPLN1 Hyaluronan And Proteoglycan Link 
Protein 1 
2.7 -2.7 
BMPR1B Bone Morphogenetic Protein Receptor 
Type 1B 
1.2 -3.0 
ZNF618 Zinc Finger Protein 618 2.8 -3.1 
 
Even though CHD7 seems to regulate distinct genes in LN-229 and LN-428 
cells, the altered genes were highly associated with pathways such as 
“biological adhesion”, “cell adhesion” and “locomotion” in gene ontology (GO) 
analysis (Fig. 6A, B and supplementary Fig. S7 online). 
Genes encoding proteins involved in cell-cell adhesion, including several 
integrins (ITGA1, ITGBL1, ITGB2, ITGB3) and protochaderins/cadherins 
(PCDH7, PCDH10, PCDH15, CDH7, CDH9 and CDH15), as well as other cell 
binding molecules, such as CADM2, CADM3, NRCAM, NRCAM2, EMILIN2 and 
CNTN1, were also modulated upon changes in CHD7 expression. 
The heat-maps indicate the top 30 DEGs in both groups (Fig. 6C, D). To 
independently validate these results, changes in the expression of 40 genes 
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associated with tumorigenesis, cell motility or invasiveness were analyzed by 
qRT-PCR (Fig. 6E, F). 
Next, we sought to compare the differentially expressed genes found in our 
model with previously described CHD7 localization determined by chromatin 
immunoprecipitation in NSCs13.  These authors revealed approximately 16,000 
binding sites near or in the gene sequences. We found that 28% (85 genes) of 
the DEGs in KO and 30% (259 genes) of the genes modulated in OE coincide 
with CHD7 binding sites previously mapped in mouse NSCs (see 
supplementary Table S6 online). These data suggest that CHD7 might have 
binding sites and/or transcriptional targets that are conserved in between 
mouse NSCs and human glioblastoma cells. 
Discussion 
CHD7 is known to be essential for organogenesis 26 and in the non-pathological 
brain, it was shown to be crucial for NSC function 13–15,27. On the other hand, the 
involvement of CHD7 in tumorigenesis has just begun to be described, gaining 
considerable attention in the last few years. 
In silico analysis of 32 tumor types revealed that CHD7 is the most commonly 
gained/amplified and mutated gene among the CHD members. The same study 
also showed that overexpression of CHD7 was more prevalent in aggressive 
subtypes of breast cancer, being significantly correlated with high tumor grade 
and poor prognosis 16. Consistent with these findings, frequent CHD7 mutations 
have been reported in stomach and colon cancers 19 and aberrations in CHD7 
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activity was suggested to contribute to colorectal carcinoma CpG island 
methylator phenotype 1 18. Moreover, low CHD7 expression in the G4 
meduloblastoma subtype, in combination with BMI1 overexpression, has 
recently been shown to contribute to tumor formation 17. Mechanistically, CHD7 
inactivation favors chromatin accessibility at BMI1 target genes, which, in turn, 
leads to ERK over-activity and increased cell proliferation. Thus, these data 
strongly suggest the association of CHD7 with the pathology of different human 
cancers. 
In the present study, we provide evidence that CHD7 plays an important role in 
glioblastoma pathogenesis, which is the most common and deadliest of 
malignant primary brain tumors in adults 28. Despite the multimodality treatment, 
which typically includes surgery, ionizing radiation, and cytotoxic chemotherapy, 
the average overall survival rate remains at only ∼15 months, highlighting the 
urgent need for more effective targeted therapeutics29. 
Our results indicate that CHD7 is highly expressed in glioma patient samples, 
as previously suggested 30. Additionally, using the CD133 cell surface marker, 
we observed that CHD7 is more expressed in the CD133 negative cell 
population in a subgroup of tumor samples. We also demonstrated that CHD7 
knockout not only inhibited anchorage-independent growth in LN-229 cells, but 
also reduced cell invasion ability. Interestingly, CD133 immunostaining in 
glioma patient samples showed that CD133 expression was significantly 
reduced in migrating tumor cells in the tumor periphery compared to tumor cells 
in the core region 31. However, the same study discusses that CD133 was found 
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at lower level compared to other stem cell markers, such as Nestin, Musashi-1 
and SOX-2. 
In vitro, CHD7 expression was found to be highly heterogeneous in the panel of 
human glioblastoma-derived cell lines analyzed consistent to what we observed 
in our set of clinical samples as well as in the TCGA public database. 
Importantly, the cell line presenting the highest CHD7 protein level was the T-
269 GIC. Ohta and colleagues have also shown that CHD7 is found to be highly 
expressed in different established GICs, when compared to normal human 
astrocytes 30, however, what specifically determines the great variability in 
CHD7 expression among these cell lines remains elusive but a warranted field 
of future investigation. 
Studies on CHD7 domain-specific functions and overexpression phenotypes are 
still scarce in the literature, possibly due to the length of the coding region 
(2,997 aa) and technical difficulties in generating expression vectors 36. A recent 
study showed that introduction of a mRNA encoding the CHD7 isoform 2 (948 
aa), in KhES-1 human embryonic stem cells, induced spontaneous cell 
differentiation in vitro and CHD7-overexpressing cell culture could not be 
maintained 32. Here, we amplified the CHD7 coding sequence as three 
overlapping fragments and the full-length was then assembled and inserted into 
the expression vector by Gateway®-assisted sub-cloning. We demonstrated 
that ectopic CHD7 expression enhanced migration and invasion capacity of LN-
428 cells, potentially by regulating stress fiber assembly and adhesion 
dynamics. Actin stress fiber formation is one of the critical steps associated with 
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cell invasion 33, but the precise mechanism by which CHD7 promotes 
reorganization of the cell cytoskeleton remains to be elucidated. We were 
unable to explore the role of CHD7 in GICs using the same approach, due to 
difficulties in selecting and expanding modified cells for experiments. 
Interestingly, CHD7 duplications have been suggested to be a driver mutation 
identified in small-cell lung cancer, one of the most highly metastatic and 
aggressive types of cancer 21. Additionally, using iPS-derived neural crest cells 
from CHARGE patients, CHD7 mutations were also found to promote defective 
cell migration 34. This study showed modulation of several genes related to cell 
adhesion and migration, such as CTGF, COL3A1, SERPINE1 and THBS1, all of 
which we found to be modulated in glioblastoma cells. CHD7 has also been 
implicated in regulation of neural crest cell migration during embryogenesis in 
Xenopus 7. In this model and also in human neural crest cells, CHD7 was 
shown to associate with PBAF to modulate SOX9 and TWIST1 gene 
expression, which are essential for proper cell migration of this cell type. We did 
not observe significant changes in those genes in our model, indicating that 
CHD7 may regulate cell motility by different mechanisms, possibly by 
association with cell-specific interaction partners. 
In fact, it has been previously shown that CHD7 binding sites present high 
variability among different cell types and CHD7 binding itself is context-
dependent (e.g., embryonic cell in the differentiated state showed only 30% 
overlap in the binding sites) 10. In our study, 18 genes were commonly regulated 
in opposite directions in LN-229 and LN-428 cell lines. Moreover, the 
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comparison with previously described CHD7 binding sites reveled that genes 
modulated by CHD7 perturbation in glioblastoma cells, such as NRCAM, 
CNTN1 and EMILIN2, have significantly higher enrichment of CHD7 occupancy 
in mouse NSCs 13, suggesting direct transcription modulation of these targets. 
Importantly, several of these genes have been implicated in glioblastoma 
invasiveness 35. 
One could argue that each cell type in a given tissue might have unique CHD7 
binding sites and protein complexes, which vary over time 36. Our findings 
demonstrate the diversity of CHD7-regulated genes and suggest a broader 
function for CHD7 as a master regulator of cell migration and invasion. It will be 
of great interest to investigate, for example, the underlying mechanism 
regulating differential CHD7 expression in glioblastoma cells and whether these 
pathways are amenable to manipulation by molecular intervention aiming at 
clinical therapeutic trials. 
Conclusions 
The invasive behavior of malignant gliomas is one of the most important 
characteristic which contributes to tumor recurrence after surgery 37. Our data 
provides functional and molecular evidences for a novel oncogenic role of 
CHD7 as a transcriptional regulator of pro-invasive and motility factors in 
glioblastoma cells (Fig. 6G). Further studies may warrant important clinical-
translational implications for glioblastoma treatment. 
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Methods 
Gene expression and survival analysis using The Cancer Genome Atlas 
(TCGA) dataset 
Overall expression analysis within the TCGA database 
(http://cancergenome.nih.gov) was undertaken using the single gene 
expression analysis module of the R2: microarray analysis and visualization 
platform (http://www.r2.amc.nl). CHD7 expression clusters were generated 
across 276 samples (MAS5.0 - u133p2 dataset) and analyzed with k-means 
algorithm and log2 transformation of gene expression. Analysis of CHD7 
expression relative to the glioblastoma subtype 24 was carried out using 435 
samples classified into these groups within the subtype track mode and z-score 
transformation. Kaplan-Meier survival analysis and log-rank tests were carried 
out as detailed in Supplementary Information online.  
Patient samples 
Brain tissue samples from temporal lobectomy epileptic patients and from 
resected astrocytoma specimens were macro-dissected and immediately snap-
frozen in liquid nitrogen 38. The specimens were categorized according to the 
2007 WHO classification 23. This project has the approval of the Ethical 
Committee of the University of São Paulo School of Medicine (CAPPesq, 
691/05), and informed consent was obtained from all patients. The CD133pos 
and CD133neg cells were isolated from freshly resected human glioblastoma 
tumor tissue (ZH-419, ZH-445, ZH-456, ZH-464, ZH-496 and ZH-525) after 
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written informed consent of the patients and approval by the Institutional Review 
Board of the University Hospital Zurich. Detailed protocol described in 
Supplementary Information online. 
In vitro assays 
Details on cell lines, reagents, real-time quantitative reverse transcription-PCR 
(qRT-PCR) and primers, are provided in Information online. Detailed protocol 
for immunofluorescence, anchorage-independent clonal growth, migration and 
invasion assays is summarized in Supplementary Information online. 
CRISPR/Cas9 knockout of CHD7 
CHD7 knockout clones were generated according to the protocol described by 
Ran and colleagues 39. Briefly, small guide RNAs (sgRNAs) were designed, 
using an online CRISPR Design Tool (http://tools.genome-engineering.org) and 
then cloned (guide sequences in Supplementary Material and Methods Table 
S2) into the pSpCas9(BB)-2A-Puro (PX459), a gift from Feng Zhang (Addgene 
plasmid #48139, Addgene, Massachusetts, USA). Lipofectamine 2000 (Life 
Technologies) was used for transient co-transfection of two sgRNAs constructs 
at a 1:1 ratio. Cells were selected with 3 μg/mL puromycin (Life Technologies) 
for 48h and genomic DNA was extracted using QIAamp DNA Kit (Qiagen, 
 Venlo, Netherlands) for detection of the CHD7 deletion by PCR (primer 
sequences available in Supplementary Information Table S3 online). 
Transfected cells were then isolated by BD FACSARIA II (BD Bioscience) single 
cell sorting in 96 well plates. Cell clones were expanded for genomic DNA 
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extraction and genotyping (Supplementary Fig. S3). Selected clones were 
further expanded for nuclear protein extraction and tested by immunoblotting. 
CDH7 overexpression 
A 9Kb cDNA, comprising the ORF full-length of the human CHD7 gene 
(GenBank Accession #NM_017780.3) was amplified by long RT-PCR from the 
OVCAR8 human ovarian cancer cell line as three overlapping ~3kb fragments.  
Briefly, total RNA was purified from OVCAR8 cells (RNeasy RNA Purification 
Kit, Qiagen) and 1 μg RNA was used as the template for reverse transcription 
with SuperScriptIII® (Life Technologies). PCRs were carried out using 
Phusion® High Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) 
and the resulting PCR products were cloned using TOPO® Zero Blunt cloning 
kit (Thermofisher). Clones displaying the correct sequence, as judged by 
Sanger sequencing, were assembled by Gibson® cloning into the full length 
ORF using the unique AflII and MfeI restriction sites of the CHD7 cDNA. A 
Kozak consensus sequence was added juxtaposed to the initial ATG codon for 
optimal expression levels in mammalian cells. The final full-length 9Kb CHD7 
cDNA was cloned into the pCXN2 expression vector 40 using the Gateway®-
assisted sub-cloning. 
To generate OE cell populations, cells were transfected with the pCXN2_CHD7 
construct or with the empty vector using Lipofectamine 2000 (Life 
Technologies). LN-428 and A172 transfected cells were selected with 750 
µg/mL and 200 µg/mL of Geneticin G418 Sulfate (Gibco, Thermo Scientific), 
respectively. 
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Histology and immunohistochemistry 
Three glioblastoma patient samples (ZH149, ZH265, ZH276) and one normal 
brain tissue were used to investigate CHD7 protein levels. Samples were de-
paraffinized and rehydrated tumor tissue sections were boiled in EDTA buffer, 
pre-treated with 1% H2O2 and blocked in blocking solution (Candor Biosciences, 
Germany). Sections were incubated with primary anti-CHD7 antibodies 
(ab31824, 1/200) (Abcam, Cambridge, UK) at 4°C overnight. Simultaneously 
and under the same conditions, matching rabbit IgG isotype control (ab27478, 
1/200) was used in place of the CHD7 primary antibody for accurate 
interpretation of immunostaining results. After washing, samples were incubated 
with goat anti-rabbit IgG-AP (sc2007, 1/200) (Santa Cruz, Texas, USA) at room 
temperature for 30 min (under protection from light). The DAB+ (#K3468, Dako) 
chromogen substrate was used as the detection system and the sections were 
counterstained with Mayer's hematoxylin to visualize the nuclei. 
Tumor-bearing brains were embedded in cryomoulds in Shandon Cytochrome 
yellow (Thermo Scientific, Waltham, MA) and frozen in liquid nitrogen. Tumor 
incidences and sizes were determined using (H&E)-stained 8 μm thick 
cryosections using a Microm HM560 (Microchom HM560, Thermo Scientific). 
Immunoblotting 
Total cellular extracts were obtained by lysing cells with RIPA buffer (150 mM, 
NaCl, 1% NP-40, 0.5% SDS, 50 mM Tris pH 8.2, 1 mM EDTA). Cytoplasm and 
nuclear protein lysates were prepared with the NE-PER Nuclear and 
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Cytoplasmic Extraction kit (Thermo Scientific). Proteins (30 µg per lane) were 
resolved on a 3 to 7% Tris-acetate gel (Life Technologies) to detect CHD7 and 
PARP1. Actin was evaluated in a 10% SDS-PAGE. Gels were transferred to a 
nitrocellulose membrane (Life Technologies). After blocking with 0.5% non-fat 
milk in TBS containing 0.5% Tween 20 (TBST), the membrane was incubated in 
blocking solution with primary antibody overnight at 4°C. After washing and 
incubation with the HRP-conjugated secondary antibody (1/5,000, Sigma 
Aldrich), the protein bands were detected with enhanced chemoluminescence 
(ECL, Thermo Scientific). Original blots are presented in Supplementary 
Information, Figure S8 online. 
RNA-seq experiment and data analysis 
The next-generation sequencing (NGS) libraries were prepared according to 
Illumina TruSeq Stranded mRNA LT protocol. Quality control of the amplified 
products before and after fragmentation and labeling was analyzed using the 
Agilent Bioanalyzer. Samples were sequenced on Illumina NextSeq 550 (2 x 76 
bp paired-end sequencing) operated by the Biomedical Institute Facility Center 
CEFAP of the University of São Paulo (USP). All calculations were carried out 
as described in Supplementary Information online.  
Animal studies 
All experiments were carried out according to the Swiss Federal Law on the 
Protection of Animals, the Swiss Federal Ordinance on the Protection of 
Animals, and the guidelines of the Swiss confederation (permission 
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#ZH062/15). FoxN1 nu/nu mice (Charles River, Sulzfeld, Germany) aged 
between 6–12 weeks were anaesthetized and placed in a stereotaxic fixation 
device. A burr hole was drilled in the skull 2 mm lateral and 1mm posterior to 
the bregma. The needle of a Hamilton syringe was introduced into a depth of 3 
mm 41. LN-229 (7.5x104) and LN-428 (1x105) cells were resuspended in PBSA 
and then injected into the right striatum. Animals were clinically assessed three 
times per week and sacrificed upon developing neurological symptoms, 
justifying euthanasia (score 2). 
Statistics 
Analysis of the relative mRNA levels between different glioma grades and 
glioblastoma samples were carried out by a non-parametric analysis of variance 
(Kruskal-Wallis test) with Dunn test for post-hoc comparison. In vitro 
experiments were performed in biological and technical replicates. Results are 
expressed as the mean and SEM of triplicate determinations. The statistical 
analyses were performed by unpaired Student’s t-test or ANOVA for multiple 
comparison tests. Animal survival statistics was assessed using Gehan-
Breslow-Wilcoxon test. All statistical analyses were carried out using Prism 5 
(GraphPad Software, La Jolla, CA). 
Ethics approval and consent to participate 
Clinical human samples were obtained from patients undergoing surgical 
resection. All the procedures were performed in accordance with the guidelines 
and regulations as determined by the Ethical Committee of the University of 
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São Paulo School of Medicine (CAPPesq, 691/05), and informed consents were 
obtained from all patients. The CD133pos and CD133neg cells were isolated from 
freshly resected human glioblastoma tumor tissue after written informed 
consent of the patients and in accordance with the guidelines and regulations 
determined by the Institutional Review Board of the University Hospital Zurich. 
All animal experiments were performed in accordance with protocols approved 
by the Swiss Federal Law on the Protection of Animals, the Swiss Federal 
Ordinance on the Protection of Animals, and the guidelines of the Swiss 
confederation (permission #ZH062/15). 
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Figure Legends 
Figure 1 
CHD7 is up-regulated in gliomas. (A) CHD7 mRNA levels in 276 human brain 
tissue samples from the TCGA microarray database. Values are presented as 
log2 transformation gene normalized by median-centered Log2 ratios. (B) 
CHD7 mRNA levels in glioblastoma subtypes according to the Verhaak 
classification. Values are presented as log2 transformation gene normalized by 
median-centered Log2 ratios. (C) Relative CHD7 mRNA levels of macro-
dissected brain tissue samples from normal brain tissue (NBT) and from 
resected glioma specimens was assessed by qRT-PCR. Values are presented 
as log10. HPRT1 levels were used as internal control for normalization. Bars 
represent the mean value. *p<0.05, ** p<0.01, *** p<0.001; non-parametric 
analysis of variance (Kruskal-Wallis test) followed by Dunn’s test for post hoc 
comparison were used for statistical analysis. (D) Representative CHD7 
immunohistochemistry in NBT and in ZH276 glioblastoma patient sample. 
Isotype IgG was used as negative control. Scale bar = 20 μm. 
Figure 2 
CHD7 expression in freshly dissected tumor tissue and in human-glioblastoma 
derived cell lines. (A) Relative CHD7 mRNA levels of freshly dissociated 
CD133pos and CD133neg tumor cells were assessed by qRT-PCR. Cell fractions 
represent matched sub-populations from the same patient. Results are 
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expressed as average ± SEM for technical replicates. *** p<0.001; 2-way 
ANOVA followed by Bonferroni posttest. (B) Relative CHD7 mRNA levels in 
different LTCs and GICs, determined by qRT-PCR. The results represent 
average ± SEM from two independent experiments. # # p<0.01, *** p<0.001; 
one-way ANOVA followed by Bonferroni correction for multiple tests compared 
with LN-229 and all the other cell lines, respectively. (C) CHD7 immunoblotting 
of fractionated nuclear extracts (NE) and cytoplasmic extracts (CE) of LN-229 
and LN-319 cell lines. PARP1 and HSP90 were used as nuclear and 
cytoplasmic markers, respectively, examined consecutively in the same blot as 
CHD7, after membrane stripping. (D) CHD7 immunoblotting of nuclear extracts 
of human glioblastoma-derived cell lines. Left painel shows the result from 
LTCs. In a separated gel, right painel, is the blot from the GICs. Actin was used 
as loading control for each of the gels. Due to the great difference in the protein 
sizes, the loading control was examined in a separated gel, loaded in the same 
conditions. Total protein extract of 293T cells transfected with the empty vector 
and CHD7 overexpression plasmids were used as negative and positive 
controls, respectively. 
Figure 3 
CHD7 deletion inhibits anchorage-independent cell growth and spheroid 
invasion in LN-229 cells. (A) Strategy used to generate CHD7 KO cell clones. 
LN-229 cell line was co-transfected with two sgRNAs and selected with 
puromycin for 48h. After confirmation of genomic editing by PCR in the mixed 
population selected, we performed clonal isolation. (i-ii) indicate clones carrying 
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CHD7 mutations, which may lead to abrogation of CHD7 expression, and (iii) 
indicates isolated clones which still exhibit CHD7 expression. (B) Scheme 
indicating the sgRNA sequences targeting the 5’ and 3’ regions of the CHD7 
gene. (C) CHD7 immunoblotting of nuclear extracts from two WT and two KO 
isolated clones. PARP1 was used as the loading control, examined in the 
membrane as CHD7. (D) Growth curves of LN-229 clones. 1x104 cells were 
plated in 12 well plates in triplicates for each time point. Experiments were 
performed three times. Results are expressed as average ± SEM for three wells 
of a single experiment. *p<0.05; one-way ANOVA followed by Dunnett´s test in 
comparison with WT-1. (E) 1x104 LN-229 cells suspended in soft agar were 
layered onto the bottom agar in 24-well plates in triplicates. Representative 
images of cell colonies grown in culture medium for two weeks. Scale bar: 200 
μm. The graph represents total number of colonies per well, greater than 50 μm 
diameter. Results are expressed as average ± SEM from three independent 
experiments. *p<0.05, **p<0.01; one-way ANOVA followed by Dunnett´s test in 
comparison with WT-1. (F) Spheroids of WT and KO clones were placed in a 
3D-collagen I matrix and the area covered by invading cells was measured for 
quantification after 24, 48 and 72 h. Representative images show multicellular 
spheroids at the time point 0 h and 24 h. Scale bar: 400 µm. (G) Experiments 
were performed three times in quadruplicates for each cell clone. Results from a 
single representative experiment are presented. Results are expressed as 
average ± SEM. *p<0.05, **p<0.01, *** p<0.001; 2-way ANOVA followed by 
Bonferroni test in comparison with WT-1.  
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Figure 4 
CHD7 overexpression promotes migration and invasion of LN-428 cells in vitro. 
(A) LN-428 cells were transfected with either the EV or OE vectors and selected 
with 750 µg/mL G418. Relative CHD7 mRNA levels were assessed by qRT-
PCR and immunoblotting of nuclear cell extracts. Results are expressed as 
average ± SEM. *** p<0.001; Student’s t-test. PARP1 was used as loading 
control, examined in the same blot as CHD7. (B) Wound-healing scratch assay: 
2x105 cells were plated in 24 well plates in triplicates. Experiments were 
performed three times. Results are expressed as average ± SEM for three wells 
of a single experiment. **p < 0.01; 2-way ANOVA. (C) Representative images 
and statistical plots of transwell migration assays. (D) Representative images 
and statistical plots of transwell Matrigel coated invasion assays. Scale bar: 100 
µm. The number of cells which transversed the membrane was assessed after 
16h incubation and six independent fields at 10x magnification objective were 
counted for each well. Three independent experiments using duplicates were 
performed for each assay. Results are expressed as average ± SEM. **p<0.01; 
Student’s t-test. (E) CHD7 overexpression promotes changes in the 
cytoskeleton of LN-428 cells. The upper panel shows LN-428 EV and the lower 
panel shows LN-428 OE. White arrows indicate differential cytoskeleton 
organization in a cell that does not display high CHD7 protein level, in 
comparison with OE cells. Images were captured using confocal microscope. 
CHD7 (red), Actin filaments (green) and nuclei (blue). Scale bar: 20 µm. (F) 
Graph shows the percentage of LN-428 cells with low and high CHD7 protein 
levels which display evident stress fibers. EV and OE cells were plated in three 
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different passages and four independent fields at 20x magnification objective 
were counted for each well. *** p<0.001; Student’s t-test. 
Figure 5 
Effect of altered CHD7 expression in tumor development in vivo. (A) 7,5x104 
human LN-229 cells were orthotopically implanted into the right striatum of nude 
mice. For histological analysis, three animals per group were sacrificed on the 
same day when the first animal(s) became symptomatic. Brain sections were 
examined and tumor sizes were assessed on H&E-stained sections. Scale bar: 
100 µm. (B) Each tumor is indicated by a dot. The bar marks the 
average ± SEM (n=3, p>0.05; one-way ANOVA compared with WT clone 
followed by Bonferroni correction for multiple tests). (C) Kaplan–Meier survival 
curves (n=5; p<0.05; Gehan-Breslow-Wilcoxon test). Animals were maintained 
until the onset of clinical grade 2 symptoms. (D) Three animals per group were 
inoculated with 1x105 LN-428 cells stably transfected with EV and OE vectors. 
For histological analysis, animals were sacrificed on the same day when the 
first animal(s) became symptomatic. LN-428 tumor size was assessed on H&E-
stained sections. Each tumor is indicated by a dot. The bar marks the 
mean ± SEM (n=3, *p<0.05; Student’s t-test). (E) Representative CHD7 
immunohistochemistry in LN-428 EV and in LN-428 OE tumors. Scale bar: 20 
µm. 
Figure 6 
Differential transcriptome analysis of LN-229 KO cell clones and LN-428 OE cell 
population. (A) and (B) Gene ontology analysis indicating the most enriched 
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pathways for the significantly altered genes in the modified cell lines, defined by 
STRING database. (C) and (D) Heat-maps indicating the shortlisted genes 
which are most significantly modulated under both comparative conditions. (E) 
and (F) Validation of gene expression by qRT-PCR. CHD7 is indicated in red. 
Down-regulated (black) and up-regulated (blue) genes related to tumorigenesis, 
cell migration or cell invasion. Values are the means ± SEM (n = 3, *p<0.05, 
**p<0.01, *** p<0.001; Student’s t-test). (G) Proposed model for CHD7 
regulation of glioblastoma cell motility and invasiveness. CHD7 is recruited to 
binding sites through interactions with cell type-specific transcription factors 
(TFs) and histone modifications. The energy provided by ATP hydrolysis 
enables nucleosome translocation revealing extra TF-binding sites (yellow 
rectangle). Binding of additional TFs, associated with co-activators, promotes 
DNA accessibility favoring transcription. In glioblastoma cells, CHD7 modulates 
the expression of several adhesion molecules, such as integrins and cadherins, 
stimulating cell motility and invasiveness. 
 






